ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pirtobrutinib

Also written as “Pirtobrutinib”, “LOXO-305” and “[14C]-LOXO-305”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Mantle-Cell · Renal Insufficiency, led by 3 companies.

Drug pagePirtobrutinib: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 6, 202530 company-led studies, 12 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only2811 open or runningphase 4since Mar 6, 2025Nov 6, 2018Oct 2027phase 3 · NCT05254743
AstraZeneca10 open or runningphase 2since Jan 21, 2025Jan 21, 2025none ahead
Nurix Therapeuticsits history only11 open or runningphase 3since Mar 31, 2026Mar 31, 2026Oct 2029phase 3 · NCT07516093

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2021Named pirtobrutinibINNProposed as its International Nonproprietary Name in WHO's List 125 · before, LOXO-305
  2. Jan 21, 2025First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT06839872

TargetBeta

BTK →read by rule
“An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

The one study AstraZeneca leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell2WithdrawnJul 28, 20280

How it is read

Names in the registry

  • “Pirtobrutinib”, 26 entries
  • “LOXO-305”, 3 entries
  • “[14C]-LOXO-305”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.